Factors Affecting the Price of DIFICID

Exelon (rivastigmine), used for Alzheimer’s and Parkinson’s-related dementia, has a price shaped by several factors. 

Factors Affecting the Price of DIFICID

R&D costs for developing this cholinesterase inhibitor, including trials for efficacy and safety, contribute significantly. Patent protection initially allowed Novartis to set premium prices, though generic versions post-patent may lower costs. Production expenses, such as manufacturing oral tablets or transdermal patches with precise dosing, add to the base price. Market demand for dementia treatments and regional healthcare policies—like insurance coverage or government subsidies—also influence final costs for patients.